U.S. Markets closed

Onconova says data reinforce safety/tolerability profiles of rigosertib

Onconova Therapeutics announced two presentations relating to clinical trials of its most advanced product candidate, rigosertib, at the 55th American Society of Hematology Annual Meeting in New Orleans, Louisiana, December 7-10. The presentations included data on efficacy, tolerability, and dosing regimen from the Phase 2 ONTARGET study of oral rigosertib in transfusion-dependent, lower risk MDS patients and response, overall survival, and longer-term follow-up data from a Phase 1/2 trial of intravenous rigosertib in higher risk post-hypomethylating agent-treated MDS and acute myeloid leukemia patients. "The presentations at ASH reinforce the emerging therapeutic and safety/tolerability profiles of rigosertib, our small-molecule inhibitor of PI3K and PLK pathways, and underscore our commitment to develop rigosertib as a novel treatment for patients with MDS. We look forward to the design of an approval-track trial of oral rigosertib in transfusion-dependent, lower risk MDS and top-line data from our Phase 3 pivotal trial in higher risk MDS," the company said.